|NH -- USA Stock|| |
USD 3.18 0.11 3.58%
Dr. Patrick SoonShiong, M.D. is Chairman of the Board, Chief Executive Officer, Founder of the Company. In 2011, he founded NantWorks, an ecosystem of companies to create a transformative global health information and next generation pharmaceutical development network for the secure sharing of genetic and medical information, where he currently serves as Chief Executive Officer and Chairman of the board of directors. NantWorks is an affiliate and significant stockholder of NantHealth and Dr. Patrick SoonShiong indirectly controls all of the equity interests of NantWorks. Dr. Patrick SoonShiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields. Dr. Patrick SoonShiong performed the worlds first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nations first FDAapproved protein nanoparticle albuminbound delivery technology for the treatment of cancer. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award. Dr. Patrick SoonShiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. Dr. Patrick SoonShiong is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.
Age: 63 Founder Since 2016 Ph.D
SoonShiong serves as Chairman of the Chan SoonShiong Family Foundation and Chairman and CEO of the Chan SoonShiong Institute of Molecular Medicine, a nonprofit medical research organization. He currently cochairs the CEO Council for Health and Innovation at the Bipartisan Policy Center and is a member of the Global Advisory Board of Bank of America.